Merck to stop deliveries of Zepatier to Russia

30 August 2023
merck_msd_headquarters_rahway_large

US pharma giant Merck & Co (NYSE: MRK), known as MSD outside of the USA and Canada, will stop deliveries to Russia of Zepatier (elbasvir/grazoprevir), one of the most popular drugs against hepatitis C, reports The Pharma Letter’s local correspondent.

So far, the drug has accounted for almost 20% of all public procurement of drugs for this disease – with more than 1 billion roubles ($10.4 million) being annually spent on it.

Recently the Russian Kommersant business paper has reported, citing a letter of the Russian Ministry of Health, which warned Russian federal medical institutions about suspension of supplies and production of a number of drugs in the country, including Zepatier.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical